Search for: "Amgen Inc. v. Sanofi"
Results 1 - 20
of 105
Sorted by Relevance
|
Sort by Date
28 Sep 2023, 6:22 am
Relying on the analysis provided by the Supreme Court’s recent decision, Amgen Inc. v. [read post]
28 Sep 2023, 6:22 am
Relying on the analysis provided by the Supreme Court’s recent decision, Amgen Inc. v. [read post]
28 Sep 2023, 6:22 am
Relying on the analysis provided by the Supreme Court’s recent decision, Amgen Inc. v. [read post]
18 Jan 2024, 5:14 pm
The post USPTO Issues “Reasonable” Guidance on Enablement Under Amgen v. [read post]
4 Dec 2023, 10:00 pm
§ 112(a) as it relates to biotechnology and specifically antibody claims, addressed by the Supreme Court in Amgen Inc. v. [read post]
15 May 2023, 1:47 am
On January 26, 2023, Regeneron Pharmaceuticals, Inc., who sought to invalidate Amgen Inc. [read post]
31 May 2023, 9:43 am
Cir. 2021), the Supreme Court found Amgen's function and epitope defined PCSK9 antibody patents to lack enablement (Amgen Inc v Sanofi, No. 21-757). [read post]
3 Oct 2023, 4:15 am
The Supreme Court decided Amgen Inc. v. [read post]
3 Oct 2023, 4:15 am
The Supreme Court decided Amgen Inc. v. [read post]
1 Mar 2023, 4:15 am
The United States Supreme Court is set to hear opening arguments in Amgen Inc. v. [read post]
1 Mar 2023, 4:15 am
The United States Supreme Court is set to hear opening arguments in Amgen Inc. v. [read post]
19 Apr 2021, 6:04 am
by Dennis Crouch Amgen Inc. v. [read post]
18 May 2023, 8:20 am
The case in question is Amgen Inc. v. [read post]
26 Sep 2022, 6:39 am
” Gov’t CVSG Brief in Amgen Inc. v. [read post]
29 Apr 2021, 6:39 am
Amgen v. [read post]
9 Jul 2023, 8:40 pm
Abbott Laboratories", "Enzo Life Sciences, Inc. v. [read post]
24 Jul 2024, 4:35 am
This contrasts with the US revocation, based on enablement requirement, and where enablement was judged insufficient because, even from the description, the skilled person had to make an inventive effort to arrive at the millions of antibodies covered, according to the Supreme Court, by Amgen patents (21-757 Amgen Inc. v. [read post]
24 Jul 2024, 4:35 am
This contrasts with the US revocation, based on enablement requirement, and where enablement was judged insufficient because, even from the description, the skilled person had to make an inventive effort to arrive at the millions of antibodies covered, according to the Supreme Court, by Amgen patents (21-757 Amgen Inc. v. [read post]
7 Mar 2023, 9:16 pm
Sanofi may be the most closely watched patent case since AMP v. [read post]
18 May 2023, 12:15 pm
Earlier today, the United States Supreme Court issued its decision in Amgen, Inc. v. [read post]
